Treatment Registry
TR-0819 ActiveRecorded September 2026

Compounded tirzepatide

Sold by Novi · Injection, vial · every compounded tirzepatide record

Recorded initial charges

First month

$179

first month, including required fees on record. The published monthly rate excludes one-time and annual fees; introductory and conditional rates may change. Some fee details are unverified or unpublished; this sum does not establish the full amount payable.

Medication · Month to month · recorded initial monthly payment$179

Added from the figures recorded below.

Price

TermPublished rateCharged today
Month to month

“1 month $179”

Per month$179Charged today$179
3-month plan

“3 month $149”

$149Published figureCharged todayNot verified
6-month plan

“6 month $133”

$133Published figureCharged todayNot verified
12-month plan

“12 month $129”

$129Published figureCharged todayNot verified
Price sources
Visit Novi

We earn nothing from this link. It opens Novi's website without a paid referral.

History

Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.

  • September 2026 — Entry added to the register

Sourcing and terms

PharmacyNot disclosed
PrescriberBoth
CancellationWe're so confident in our program that if you complete your first four months of treatment and don't make meaningful progress toward your goals, you'll be eligible for a full refund under our Progress Promise.
MembershipNot disclosed
Consult feeNot disclosed

Not yet checked: states.

Recorded from joinnovi.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2026 — Novi prices compounded tirzepatide under a heading that reads “Billing cycle / Per month”, so each figure is a monthly rate: $179 month to month, $149 on three months, $133 on six and $129 on twelve. The page states what the figure covers — “Price includes everything you need: consultation, care, medication, supplies, shipping and support” — and adds “No membership or hidden fees” and “Same price no matter the dose”. It never says a longer plan is paid up front, so the amount recorded as charged today is one month rather than the whole term.
  2. 2. September 2026 — Novi's home page is not where its prices are. It is titled “Summer Promo” and leads with “Was $299 Now starting at $133/mo”, the $299 struck through, beside a counter reading “Price increases in”. That counter does not appear to count down to anything: two readings hours apart on 3 September 2026 showed thirteen hours remaining and then twenty-three hours fifty-nine minutes remaining. The same page advertises “Up to $200 OFF” on semaglutide and “Up to $250 OFF” on tirzepatide, which are discounts rather than prices, and lists Mounjaro®, Ozempic®, Wegovy® and Zepbound® as “Started at $1500” with no period attached. The figures recorded here come from the product pages instead, which price each plan per month and name the billing cycle.
  3. 3. September 2026 — Novi says it serves “all 50-states and the District of Columbia”. Treatment begins without a video visit in most states, and it names Kansas, Louisiana, Mississippi, New Mexico and West Virginia as requiring a brief video or audio visit first. It also says plainly that it is not a pharmacy and does not name the pharmacy that fills its prescriptions.
  4. 4. October 2026 — Novi's terms limit service to states where its clinicians and services are available; they do not establish nationwide access. The homepage and terms checked in October 2026 did not provide a complete served-state list. Confirm eligibility for your location before paying. The earlier nationwide flag lacked supporting evidence and has been corrected; this is not a finding that Novi stopped serving any state. Sources: https://www.joinnovi.com/ and https://www.joinnovi.com/terms-of-service.

1 further note concerns other Novi programs and sit on the provider record.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0819
Medication category
compounded tirzepatide
Readings
1

Related records

Other records from Novi

All Novi programs and terms

Compounded tirzepatide at a similar price

The records either side of this one in the recorded spread. Not a ranking, and not a recommendation — a position among 374 records of the same molecule.

Cite this entry

Treatment Registry. (2026). Novi — compounded tirzepatide (TR-0819). Last verified September 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0819

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.